PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION
Anemia is an integral component of CKD. The prescribing of erythropoiesis stimulating agents (ESA) for the treatment of anemia constitutes a significant burden on health budgets. Using of continuous erythropoietin receptor activator (CERA) and convective techniques can improve health indicators and...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Institution «Institute of Nephrology NAMS of Ukraine"
2017-03-01
|
| Series: | Український Журнал Нефрології та Діалізу |
| Subjects: | |
| Online Access: | https://ukrjnd.com.ua/index.php/journal/article/view/217 |
| _version_ | 1797261416424538112 |
|---|---|
| author | V. Novakivskyy |
| author_facet | V. Novakivskyy |
| author_sort | V. Novakivskyy |
| collection | DOAJ |
| description |
Anemia is an integral component of CKD. The prescribing of erythropoiesis stimulating agents (ESA) for the treatment of anemia constitutes a significant burden on health budgets. Using of continuous erythropoietin receptor activator (CERA) and convective techniques can improve health indicators and economic results.
The aim of the study was to evaluate the effects of hemodiafiltration treatment (HDF) on the pharmaco-economic efficiency of anemia treatment in comparison with haemodialysis (HD).
Methods. A prospective cross-sectional study involving 40 patients with CKD stage V who receiving dialysis treatment at the LLC “Fresenius Medical Care Ukraine ” Medical center in Cherkasy city. The follow-up period was 2 years. First, data was analyzed while patients received HD over a period of twelve months. Then, the same patients were evaluated during treatment with HDF for at least another twelve months.
Result. The average dose of CERA reduced from 60 mg to 44 mg per month (p = 0.002) after the transferred ofpatients to HDF treatment. There were a significantly increased the levels of Kt / V (p = 0.04) and serum albumin (p = 0.04). A higher number of patients achieved the target hemoglobin results.
Conclusions. The comparison of pharmaco-economic component of anemia correction with CERA cross-sectional study demonstrates significant advantages of HDF treatment compared to HD.
|
| first_indexed | 2024-04-24T23:40:52Z |
| format | Article |
| id | doaj.art-10a072c5ed9b4a0ca9c68514e3a475a1 |
| institution | Directory Open Access Journal |
| issn | 2304-0238 2616-7352 |
| language | English |
| last_indexed | 2024-04-24T23:40:52Z |
| publishDate | 2017-03-01 |
| publisher | State Institution «Institute of Nephrology NAMS of Ukraine" |
| record_format | Article |
| series | Український Журнал Нефрології та Діалізу |
| spelling | doaj.art-10a072c5ed9b4a0ca9c68514e3a475a12024-03-15T12:23:00ZengState Institution «Institute of Nephrology NAMS of Ukraine"Український Журнал Нефрології та Діалізу2304-02382616-73522017-03-011(53)10.31450/ukrjnd.1(53).2017.04217PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATIONV. Novakivskyy0LLC «Fresenius Medical Care Ukraine» Medical Centre Anemia is an integral component of CKD. The prescribing of erythropoiesis stimulating agents (ESA) for the treatment of anemia constitutes a significant burden on health budgets. Using of continuous erythropoietin receptor activator (CERA) and convective techniques can improve health indicators and economic results. The aim of the study was to evaluate the effects of hemodiafiltration treatment (HDF) on the pharmaco-economic efficiency of anemia treatment in comparison with haemodialysis (HD). Methods. A prospective cross-sectional study involving 40 patients with CKD stage V who receiving dialysis treatment at the LLC “Fresenius Medical Care Ukraine ” Medical center in Cherkasy city. The follow-up period was 2 years. First, data was analyzed while patients received HD over a period of twelve months. Then, the same patients were evaluated during treatment with HDF for at least another twelve months. Result. The average dose of CERA reduced from 60 mg to 44 mg per month (p = 0.002) after the transferred ofpatients to HDF treatment. There were a significantly increased the levels of Kt / V (p = 0.04) and serum albumin (p = 0.04). A higher number of patients achieved the target hemoglobin results. Conclusions. The comparison of pharmaco-economic component of anemia correction with CERA cross-sectional study demonstrates significant advantages of HDF treatment compared to HD. https://ukrjnd.com.ua/index.php/journal/article/view/217anemia, hemoglobin, hemodialysis, hemodiafiltration, continuous erythropoiesis receptor activator |
| spellingShingle | V. Novakivskyy PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION Український Журнал Нефрології та Діалізу anemia, hemoglobin, hemodialysis, hemodiafiltration, continuous erythropoiesis receptor activator |
| title | PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION |
| title_full | PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION |
| title_fullStr | PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION |
| title_full_unstemmed | PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION |
| title_short | PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION |
| title_sort | pharmaco economicbenefits of correction of anemia with continuous erythropoietin receptor activator hemodialysis vshemodiafiltration |
| topic | anemia, hemoglobin, hemodialysis, hemodiafiltration, continuous erythropoiesis receptor activator |
| url | https://ukrjnd.com.ua/index.php/journal/article/view/217 |
| work_keys_str_mv | AT vnovakivskyy pharmacoeconomicbenefitsofcorrectionofanemiawithcontinuouserythropoietinreceptoractivatorhemodialysisvshemodiafiltration |